Indeed, the therapy with hydroxychloroquine plus trametinib (MEK inhibitor) is under evaluation in patients with pancreatic ductal adenocarcinoma and metastatic melanoma, in a phase II clinical trial [138,145]. This evidence concerns the gene MAP2K7 and pancreatic ductal adenocarcinoma.